<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The ability of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells to undergo invasion and migration is a prerequisite for <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">tumor metastasis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Rho, a Ras-related small GTPase, and the Rho-associated coiled coil-containing protein kinases (Rho kinases, ROCK1 and ROCK2) are key regulators of focal <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>, actomyosin contraction, and thus cell motility </plain></SENT>
<SENT sid="2" pm="."><plain>Inhibitors of this pathway have been shown to inhibit <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell motility and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we show that fasudil [1-(5-isoquinolinesulfonyl)-homopiperazine], an orally available inhibitor of Rho kinases, and its metabolite 1-(hydroxy-5-<z:chebi fb="0" ids="16092">isoquinoline</z:chebi> <z:chebi fb="0" ids="29825">sulfonyl</z:chebi>-homopiperazine) (fasudil-OH) modify <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell <z:mp ids='MP_0000002'>morphology</z:mp> and inhibit <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">tumor cell migration</z:e> and anchorage-independent growth </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, we show that fasudil inhibited <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> in three independent animal models </plain></SENT>
<SENT sid="5" pm="."><plain>In the MM1 peritoneal dissemination model, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden and <z:hpo ids='HP_0001541'>ascites</z:hpo> production were reduced by &gt; 50% (P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>In the HT1080 experimental lung <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> model, fasudil decreased lung nodules by approximately 40% (P &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>In the orthotopic <z:hpo ids='HP_0003002'>breast cancer</z:hpo> model with <z:chebi fb="14" ids="32506">MDA</z:chebi>-MB-231, there were 3-fold more <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-free mice in the fasudil-treated group versus saline control group (P &lt; 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>Fasudil has been approved for the treatment of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> and associated cerebral ischemic symptoms </plain></SENT>
<SENT sid="9" pm="."><plain>In patients, fasudil is well tolerated without any serious adverse reactions </plain></SENT>
<SENT sid="10" pm="."><plain>Therefore, the concept of Rho kinase inhibition as an antimetastatic therapy for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> can now be clinically explored </plain></SENT>
</text></document>